RareResearch.AI
← Back to atlas

Y669C

Category 3/4 — Most DruggableLikely pathogenicLumenal · predictedσ-1 candidateEditorial
TyrosineCysteine at position 669 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Tyrosine → Cysteine at position 669 in wolframin's C-terminal lumenal domain. ClinVar Likely pathogenic, associated with classical autosomal recessive Wolfram syndrome 1. AlphaMissense 0.998, DynaMut2 ΔΔG -0.41 kcal/mol (destabilising). One of the six pilot variants in the Atlas.

Interactive 3D Structure

Wild-type reference
Wild-type Y669 — hydrogen bond to T665
Fullscreen ↗
DynaMut2 mutant · Y669C
Mutant C669 — hydrogen bond to G834 lost (10 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

10 lost1 gained12 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondT665T665Preserved
Hydrogen bondW666Gained
Hydrogen bondL672L672Preserved
Hydrogen bondC673C673Preserved
Hydrogen bondG834Lost
Polar contactT665T665Preserved
Polar contactW666W666Preserved
Polar contactA671Lost
Polar contactL672L672Preserved
Polar contactC673C673Preserved
Polar contactL833Lost
Polar contactG834Lost
Aromatic / πW666Lost
Aromatic / πW700Lost
Van der WaalsA671A671Preserved
Van der WaalsC673C673Preserved
HydrophobicL664L664Preserved
HydrophobicW666W666Preserved
HydrophobicC673Lost
HydrophobicL693Lost
HydrophobicW700W700Preserved
HydrophobicL829Lost
HydrophobicL833Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.41kcal/mol
Destabilising — mild
AlphaMissense
0.998
LPath
AlphaFold pLDDT
88
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Standard confidence · Lumenal

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationLikely pathogenic
Review statuscriteria provided, single submitter
Associated conditionsWolfram syndrome 1
InheritanceAutosomal recessive Wolfram syndrome 1 phenotype documented in ClinVar.
Population frequency (gnomAD v4)Ultra-rare · AF 0.00014%
cDNA changec.2006A>G
ClinVar accessionVCV002576526
Last evaluated2023/08/15 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Likely pathogenic for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). Classic Wolfram syndrome is recessive: a single copy does not produce it, and this classification says nothing about a carrier's own risk.

  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • This rests on a single submitter (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.00014% · 2 / 1,461,066 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.00018%

Highest in European (non-Finnish): AF 0.00018% (2 of 1,111,992 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.00018%2 / 1,111,9920~1 in 278000

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 669 sits in wolframin's C-terminal lumenal domain (residues 653–869). The AlphaFold model places Y669 within 5 Å of GLN668 (2.5 Å), GLY670 (2.5 Å), TRP666 (3.8 Å), THR665 (4.0 Å), ALA671 (4.4 Å), and GLN667 (4.5 Å). The wild-type tyrosine ring sits in an aromatic-adjacent environment — TRP666 at 3.8 Å is consistent with edge-face π–π stacking between the Y669 phenol and the W666 indole. The hydroxyl group of the wild-type also makes plausible hydrogen-bonding contacts to GLN668 and THR665.

Replacing tyrosine with cysteine at this position has three layered effects. First, the aromatic ring is gone, eliminating the π-stacking with TRP666 and the hydrophobic surface contributed to the local fold. Second, the hydroxyl group is gone, removing two hydrogen-bond contacts. Third, a reactive free thiol is introduced into the oxidizing ER lumen — and the lumenal domain contains other cysteine residues (notably CYS673 at 3.8 Å from C690, a separate position) that could engage in aberrant disulfide formation. The new C669 is not directly in contact with another cysteine in the AlphaFold model, but disulfide chemistry in an oxidizing compartment is promiscuous.

DynaMut2 returns a modest |ΔΔG| of 0.41 kcal/mol. The fold survives the substitution. The damage is mechanistic — lost aromatic packing, lost H-bonding, plus the off-pathway disulfide risk that DynaMut2's structural prediction cannot fully capture.

Amino-acid chemistry
Tyrosine (Y) → Cysteine (C) — a large aromatic ring carrying a hydroxyl group replaced by a small thiol-bearing residue. Loss of aromatic packing and H-bond capacity; introduction of a reactive free thiol into the oxidizing ER lumen.
Position in the protein
C-terminal lumenal domain · position 669 sits in the ER lumen in a well-folded region (pLDDT 88). The oxidizing lumenal environment is structurally relevant: any newly-introduced cysteine here can participate in aberrant disulfide chemistry.

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.41 kcal/mol — fold intact. AlphaMissense 0.998 confirms severe functional consequence despite the modest structural cost.

The mechanism is layered: aromatic stacking with TRP666 broken, hydrogen bonding to GLN668/THR665 lost, and a new free thiol introduced into a compartment where it can form aberrant disulfides. Site-directed small molecules that occupy the lost aromatic packing footprint and/or block the introduced thiol are the rational therapeutic vector.

Compare with Y669H at the same position (Atlas card adjacent): Y669H preserves more of the aromatic character but introduces titratable basicity, and shows a stronger ΔΔG of -1.2 kcal/mol. The two variants together illustrate how substitution chemistry at a single position drives different mechanism and severity.

Why this matters

Y669C is one of the six pilot variants the Atlas was built around (R558C, A716T, G695V, L543R, A48V, Y669C). It exemplifies the lumenal domain's vulnerability to substitutions that disrupt aromatic-aromatic π-stacking — a structural feature wolframin's lumenal fold appears to depend on heavily. Drug discovery aimed at this position should target the W666 aromatic environment as the rescue surface.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the Y669C PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download Y669C PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal
Natural variant669669 · in WFS1; dbSNP:rs1402999203
Natural variant669669 · in DFNA6